Related Experiment Videos
Pharmacokinetic analysis of vancomycin in steady state in pediatric cancer patients
N Krivoy1, S Peleg, S Postovsky
1Rambam Medical Center, Haifa, Israel. N_Krivoy@rambam.health.gov.il
Insights
Vancomycin pharmacokinetics in children with malignancies showed faster clearance and shorter half-life compared to controls. The standard dose is safe but individual dosing is recommended for optimal vancomycin therapy.
Area of Science:
- Pediatric Pharmacology
- Infectious Diseases
- Oncology
Background:
- Neutropenic fever and suspected staphylococcal bacteremia are serious concerns in pediatric oncology.
- Vancomycin is a critical antibiotic for treating infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
- Understanding vancomycin pharmacokinetics is essential for optimizing therapeutic efficacy and minimizing toxicity in pediatric patients.
Purpose of the Study:
- To evaluate the steady-state pharmacokinetics of vancomycin in pediatric patients with malignancies.
- To compare vancomycin pharmacokinetic parameters between children with malignancies and those with proven MRSA infections.
- To assess the safety and efficacy of a standard vancomycin dosing regimen in this population.
Main Methods:
- A pharmacokinetic study was conducted on 30 children with malignancies and 8 children with proven MRSA infections.
- All participants received intravenous vancomycin at 40 mg/kg/day, divided into four doses.
- Pharmacokinetic parameters were calculated using a one-compartment model with two blood samples.
Main Results:
- Children with malignancies exhibited a significantly shorter half-life (t1/2) and higher clearance compared to the control group (P < .05).
- The minimum vancomycin concentration (Cmin) was significantly lower in the malignancy group (P = .03).
- The standard vancomycin dose achieved adequate peak blood levels, suggesting safety and potential efficacy.
Conclusions:
- The standard vancomycin dose of 40 mg/kg/day appears safe for pediatric patients with malignancies and neutropenic fever.
- Individual pharmacokinetic profiling is crucial for optimizing vancomycin dosing to ensure therapeutic drug concentrations.
- Further studies may be warranted to refine dosing strategies based on individual patient characteristics.
Abstract:
Thirty children suffering from different types of malignancies, neutropenic fever, and suspected staphylococcal bacteremia were evaluated for the pharmacokinetics of vancomycin in steady-state conditions and compared with eight children suffering from proven methicillin-resistant staphylococcal infection. All the studied population received intravenous vancomycin at 40 mg/kg daily divided into four daily doses. The individual pharmacokinetic parameters were calculated using a one-compartment model for two blood vancomycin samples. The mean (+/- SD) half-time (t1/2, hours), clearance (L/h/kg), Vss (L/kg), Cmax (microgram/mL), and Cmin (microgram/mL) were 10.5 (7.9) and 14.9 (9.1) hours; 0.11 (0.14) and 0.06 (0.06) L/h/kg; 0.62 (0.33) and 1.3 (0.6) L/kg; 28.3 (11.8) and 22.3 (9.8) micrograms/mL; and 5.7 (6.0) and 7.4 (4.8) micrograms/mL for the malignancy and control groups, respectively. The malignancy group had a significantly shorter t1/2 (P = .005), higher clearance (P = .005), and lower Cmin (P = .03) in comparison with the control group. It is suggested that the prescription of vancomycin at 40 mg/kg daily, divided into four daily doses, is safe and will provide a peak blood level of vancomycin sufficient to cover the broad spectrum of staphylococcal bacteria. The vancomycin dose should be individualized, based on an individual pharmacokinetic profile.